transthyretin cardiac amyloidosis
Cardiovascular · 2021–2021
2decisions
1medicine
2carried consumer input
22individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tafamidis Treatment of patients with wild-type or variant transthyretin cardiac amyloidosis (ATTR-CM) with NYHA class I-II heart failure and end-diastolic… | Sep 2021 | Not recommended | 11 individuals |
| tafamidis Treatment of patients with transthyretin cardiac amyloidosis (ATTR-CM) with wild-type or variant transthyretin, evidence or history of heart failure, NYHA… | Mar 2021 | Not recommended | 11 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.